A phase I study of recombinant Human CD40L in patients with advanced solid tumours or intermediate- or high-grade non-Hodgkin's lymphoma demonstrated encouraging antitumour activity, including a long-term complete remission (Vonderheide et al, 2001). This evidence concerns the gene CD40LG and non-Hodgkin lymphoma.